Abstract:Objective: To investigate effects of lipid lowering drug, simvastatin, on apolipoprotein M expression in the hyperlipidemic mice and in hepatic cell line, HepG2 cells. Methods: Swiss male mice were randomly divided into the high fat group and control group, and were intragastrically fed with 0.9% saline (control group) or lipid emulsion (high fat group) at the daily dosage of 15 ml/kg body weight, respectively. After 8 weeks feeding, the hyperlipidemic model was successfully induced and these hyperlipidemic mice were then randomly divided into three experimental groups: vehicle control group, high-dose simvastatin-treated group (100 mg/kg body weight), and low-dose simvastatin-treated group (10 mg/kg body weight). Mice were dosed daily for 6 weeks of simvastatin before mice were sacrificed for determining serum lipid profile and apoM protein levels that was determined by using dot blotting analysis. Effects of simvastatin on apoM mRNA expression in the HepG2 cells were determined by real-time RT-PCR. Results: Comparing to high fat model mice without simvastatin treatment, 100 mg/kg simvastatin could significantly increase serum total cholesterol (P < 0.05). Serum apoM levels, in all mice, were significantly lower in the mice at the age of 26 weeks than the mice at 12 weeks old (P < 0.05), which indicated that serum apoM levels were significantly correlated to the mice age. It demonstrated also that treatment of simvastatin did not influence serum apoM levels in these mouse model, although serum apoM levels were increased by about 13% in the 10 mg/kg simvastatin group than in the vehicle control group without simvastatin. In HepG2 cell cultures, simvastatin could significantly decrease apoM mRNA levels with dose- and time-dependent manners. At 10 μM simvastatin treatment, apoM mRNA decreased by 52% compared to the controls. Conclusion: The present study suggested that simvastatin, in vivo, had no effect on apoM levels in the hyperlipidemic mouse model. ApoM serum levels in mice were significantly correlated to the animal's age, whereas in cell cultures simvastatin does inhibit apoM expression in the HepG2 cells. The mechanism behind it is not known yet.

Effect of Apolipoprotein E Genetic Polymorphism on Fluvastatin Inhibitory Activity of 3-Hydroxy-3-methyl Glutaric Acyl Coenzyme A Reductase in L-02 Cell

The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis.

Combined effects of atorvastatin and soybean isoflavones on hypercholesterolemia and lipoprotein metabolism

Inhibition of major histocompatibility complex classⅡexpression in endothelial cells by fluvastatin

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

Effect of Atorvastatin on HMG -Coa Reductase Expression in Spontaneously Hypertensive Rats

[Effects of ApoE gene polymorphism on the efficacy of atorvastatin in the treatment of hyperlipidemia]

The Influence of Genetic Polymorphisms in Drug Metabolism Enzymes and Transporters on the Pharmacokinetics of Different Fluvastatin Formulations

Effect of simvastatin on cholesterol efflux and expression of ABCA1 and CD36 in THP-1 macrophages

Relationship between the polymorphisms in the cholesterol ester transfer protein gene and the effect of fluvastatin

Comparison of efficacy of rosuvastatin and artovastatin in treatment of hypercholesterolemia

[Influence of ApoE gene polymorphisms on therapeutic effects of lipid-lowering statins among patients with ischemic cerebral infarction]

Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke

Effect of Atorvastatin on the Expression of Apolipoprotein M

Effect of Atorvastatin on mRNA Expression of Liver X Receptor α and Its Target Gene in Human Umbilical Vein Endothelial Cells Induced by Lipopolysacharide

Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases.

Fluvastatin Blunts The Effect Of A High-Fat Meal On Plasma Triglyceride And High-Sensitivity C-Reactive Protein Concentrations In Patients At High Risk For Cardiovascular Events

Effects and mechanism of simvastatin and fenofibrate on the expression of hepatic apolipoprotein M in mice

Effects of simvastatin on apolipoprotein M in vivo and in vitro

Novel function of fluvastatin in attenuating oxidized low-density lipoprotein-induced endothelial cell ferroptosis in a glutathione peroxidase4- and cystine-glutamate antiporter-dependent manner

The Effect of Different Doses of Fluvastatin on Inflammatory Markers in the Early Phase of Acute Coronary Syndrome